Vascular dysfunction in human and rat cirrhosis: Role of receptor‐desensitizing and calcium‐sensitizing proteins

In cirrhosis, vascular hypocontractility leads to vasodilation and contributes to portal hypertension. Impaired activation of contractile pathways contributes to vascular hypocontractility. Angiotensin II type 1 receptors (AT1‐Rs) are coupled to the contraction‐mediating RhoA/Rho‐kinase pathway and may be desensitized by phosphorylation through G‐protein‐coupled receptor kinases (GRKs) and binding of β‐arrestin‐2. In the present study, we analyzed vascular hypocontractility to angiotensin II in cirrhosis. Human hepatic arteries were obtained during liver transplantation. In rats, cirrhosis was induced by bile duct ligation (BDL). Contractility of rat aortic rings was measured myographically. Protein expression and phosphorylation were analyzed by Western blot analysis. Immunoprecipitation was performed with protein A–coupled Sepharose beads. Myosin light chain (MLC) phosphatase activity was assessed as dephosphorylation of MLCs. Aortas from BDL rats were hyporeactive to angiotensin II and extracellular Ca2+. Expression of AT1‐R and Gαq/11,12,13 remained unchanged in hypocontractile rat and human vessels, whereas GRK‐2 and β‐arrestin‐2 were up‐regulated. The binding of β‐arrestin‐2 to the AT1‐R was increased in hypocontractile rat and human vessels. Inhibition of angiotensin II–induced aortic contraction by the Rho‐kinase inhibitor Y‐27632 was pronounced in BDL rats. Basal phosphorylation of the ROK‐2 substrate moesin was reduced in vessels from rats and patients with cirrhosis. Analysis of the expression and phosphorylation of Ca2+‐sensitizing proteins (MYPT1 and CPI‐17) in vessels from rats and patients with cirrhosis suggested decreased Ca2+ sensitivity. Angiotensin II–stimulated moesin phosphorylation was decreased in aortas from BDL rats. MLC phosphatase activity was elevated in aortas from BDL rats. Conclusion: Vascular hypocontractility to angiotensin II in cirrhosis does not result from changes in expression of AT1‐Rs or G‐proteins. Our data suggest that in cirrhosis‐induced vasodilation, the AT1‐R is desensitized by GRK‐2 and β‐arrestin‐2 and that changed patterns of phosphorylated Ca2+‐sensitizing proteins decrease Ca2+ sensitivity. (HEPATOLOGY 2007;45:495–506.)

[1]  T. Sauerbruch,et al.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis , 2006, Gut.

[2]  K. Jakobs,et al.  Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. , 2006, Gastroenterology.

[3]  V. Shah,et al.  Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. , 2006, Journal of hepatology.

[4]  R. Lefkowitz,et al.  Angiotensin II–Stimulated Signaling Through G Proteins and β-Arrestin , 2005, Science's STKE.

[5]  R. Lefkowitz,et al.  Seven-Transmembrane Receptor Signaling Through β-Arrestin , 2005, Science's STKE.

[6]  Don C Rockey,et al.  A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension , 2005, Nature Medicine.

[7]  T. Unger,et al.  The AT2 receptor—A matter of love and hate , 2005, Peptides.

[8]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[9]  Xuesong Chen,et al.  Impaired agonist-dependent myosin phosphorylation and decreased RhoA in rat portal hypertensive mesenteric vasculature. , 2005, American journal of physiology. Gastrointestinal and liver physiology.

[10]  J. Violin,et al.  β-Arrestin 1 and Gαq/11 Coordinately Activate RhoA and Stress Fiber Formation following Receptor Stimulation* , 2005, Journal of Biological Chemistry.

[11]  R. Lefkowitz,et al.  Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Carey.  Update on the role of the AT2 receptor , 2005, Current opinion in nephrology and hypertension.

[13]  J. Violin,et al.  beta-Arrestin 1 and Galphaq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. , 2005, The Journal of biological chemistry.

[14]  R. Lefkowitz,et al.  Seven-transmembrane receptor signaling through beta-arrestin. , 2005, Science's STKE : signal transduction knowledge environment.

[15]  F. Luft,et al.  Insights into angiotensin II receptor function through AT2 receptor knockout mice. , 2004, Acta physiologica Scandinavica.

[16]  M. Ikebe,et al.  Dynamic changes in expression of myosin phosphatase in a model of portal hypertension. , 2004, American journal of physiology. Heart and circulatory physiology.

[17]  I. Colle,et al.  Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study , 2004, European journal of gastroenterology & hepatology.

[18]  R. Challiss,et al.  Non-visual GRKs: are we seeing the whole picture? , 2003, Trends in pharmacological sciences.

[19]  ToshihiroIchiki,et al.  Cellular Mechanism of Vasoconstriction Induced by Angiotensin II , 2003 .

[20]  Katsuya Hirano,et al.  Cellular mechanism of vasoconstriction induced by angiotensin II: it remains to be determined. , 2003, Circulation research.

[21]  R. Lefkowitz,et al.  Multifaceted roles of β-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling , 2003 .

[22]  A. Somlyo,et al.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. , 2003, Physiological reviews.

[23]  S. Bolz,et al.  Nitric Oxide‐Induced Decrease in Calcium Sensitivity of Resistance Arteries Is Attributable to Activation of the Myosin Light Chain Phosphatase and Antagonized by the RhoA/Rho Kinase Pathway , 2003, Circulation.

[24]  H. Qian,et al.  Arresting angiotensin type 1 receptors , 2003, Trends in Endocrinology & Metabolism.

[25]  H. Nischalke,et al.  Portal hypertension is associated with increased mRNA levels of vasopressor G‐protein‐coupled receptors in human hepatic arteries , 2003, European journal of clinical investigation.

[26]  Toshio Kitazawa,et al.  Phosphorylation of the myosin phosphatase targeting subunit and CPI‐17 during Ca2+ Sensitization in Rabbit Smooth Muscle , 2003, The Journal of physiology.

[27]  T. Unger,et al.  Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function , 2003, Blood pressure.

[28]  R. Groszmann,et al.  Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[29]  R. Groszmann,et al.  The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough , 2002, Hepatology.

[30]  R. Lefkowitz,et al.  The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.

[31]  D. Helfman,et al.  Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts. , 2002, Molecular biology of the cell.

[32]  T. Sauerbruch,et al.  Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: Evidence for a receptor‐specific mechanism , 2001, Hepatology.

[33]  R. Lefkowitz,et al.  Beta-Arrestins: new roles in regulating heptahelical receptors' functions. , 2001, Cellular signalling.

[34]  V. Shah,et al.  Cellular and molecular basis of portal hypertension. , 2001, Clinics in liver disease.

[35]  T. Unger,et al.  Angiotensin and its AT2 receptor: new insights into an old system , 2001, Regulatory Peptides.

[36]  R. Lefkowitz,et al.  Expanding roles for beta-arrestins as scaffolds and adapters in GPCR signaling and trafficking. , 2001, Current opinion in cell biology.

[37]  P. Hadoke.  Cirrhosis of the liver and receptor-mediated function in vascular smooth muscle. , 2001, Pharmacology & therapeutics.

[38]  S. Ferguson,et al.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.

[39]  T. Cadoux-Hudson,et al.  The presence of an extractable substance in the CSF of humans with cerebral vasospasm after subarachnoid haemorrhage that correlates with phosphatase inhibition. , 2000, Biochimica et biophysica acta.

[40]  T. Unger.  The angiotensin type 2 receptor: variations on an enigmatic theme. , 1999, Journal of hypertension.

[41]  M. Bünemann,et al.  G‐protein coupled receptor kinases as modulators of G‐protein signalling , 1999, The Journal of physiology.

[42]  T. Sauerbruch,et al.  Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. , 1999, Gastroenterology.

[43]  X. Wu,et al.  Pharmacomechanical coupling: the role of calcium, G-proteins, kinases and phosphatases. , 1999, Reviews of physiology, biochemistry and pharmacology.

[44]  P. Hayes,et al.  In vitro evidence for vascular hyporesponsiveness in clinical and experimental cirrhosis. , 1997, Pharmacology & therapeutics.

[45]  N. Bunnett,et al.  Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. , 1997, The Biochemical journal.

[46]  G. Boeckxstaens,et al.  The role of increased nitric oxide in the vascular hyporeactivity to noradrenaline in long-term portal vein ligated rats. , 1995, Journal of hepatology.

[47]  R. Groszmann.  Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences , 1994, Hepatology.

[48]  Toshio Kitazawa,et al.  Correlation between high temperature dependence of smooth muscle myosin light chain phosphatase activity and muscle relaxation rate. , 1994, The Journal of biological chemistry.

[49]  R. Groszmann,et al.  Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. , 1983, The American journal of physiology.